She would have periods in time where she’d suddenly wake up in the middle of the day and she couldn’t remember anything from ...

If Medicare were to start covering popular weight loss drugs such as Wegovy and Zepbound, it could increase federal spending ...

France is the latest European country to refuse to cover weight loss drugs through its national insurance programme.View on ...

Therapies that deliver hydrogen sulfide to cells could one day become the basis of new treatments for obesity and related ...

There’s a war brewing over blockbuster weight loss medications — and patients are now getting caught in the crossfire.

The U.S. Food and Drug Administration on Friday agreed to reconsider its recent decision barring drug compounders from ...

A new national survey shows that, despite intense marketing, most Americans do not want the new weight-loss injectables, such ...

With the resolution, compounding pharmacies are no longer able to produce tirzepatide. And the FDA highlighted the point to ...

Men, baby boomers, and postgraduate-degree holders were among those most likely to say they wouldn’t choose medication over ...

Fewer than 20% of large employers are covering GLP-1 weight loss drugs like Ozempic, a new KFF analysis shows.

That’s according to a new Employer Health Benefits Survey from KFF (formerly the Kaiser Family Foundation). But while a ...

Only a fifth of large U.S. companies cover pricey GLP-1 weight-loss drugs like Wegovy and Zepbound in their health insurance ...